How should I dose omega‑3 supplements with capsule strengths of 350 mg, 235 mg, 90 mg, and 597 mg to achieve the recommended daily EPA + DHA intake?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Omega-3 Dosing Recommendations

For general cardiovascular health in adults without documented coronary heart disease (CHD), take enough capsules daily to achieve at least 500 mg combined EPA+DHA, which based on your capsule strengths (350 mg + 235 mg + 90 mg + 597 mg = 1,272 mg total omega-3 per capsule) would be met with 1 capsule daily. However, the specific EPA and DHA content of your formulation is critical—if these four numbers represent different omega-3 components rather than EPA+DHA specifically, you need to verify the actual EPA+DHA content on your supplement label.

Understanding Your Supplement Composition

The dosing numbers you've provided (350-235-90-597 mg) likely represent:

  • Different omega-3 fatty acid components (EPA, DHA, other omega-3s)
  • Or possibly different capsule strengths in a multi-capsule product

Critical point: Only EPA and DHA content matters for cardiovascular benefit—not total omega-3 content 1.

Evidence-Based Dosing by Clinical Indication

For Primary Prevention (No Heart Disease)

  • Target: 500 mg/day EPA+DHA combined 2
  • This can be achieved through 2 servings of fatty fish weekly OR supplements 3, 1
  • Minimum effective dose: 250 mg/day EPA+DHA 2, 4

For Documented Coronary Heart Disease

  • Target: 1,000 mg (1 gram)/day EPA+DHA 1, 2
  • Should preferably come from oily fish, but supplements are acceptable after physician consultation 3, 1
  • This dose showed 20% reduction in overall mortality and 45% reduction in sudden death in the GISSI trial 5

For Hypertriglyceridemia (Triglycerides 150-499 mg/dL)

  • Target: 2-4 grams/day EPA+DHA 3, 1, 2
  • Must be provided as capsules under physician care 1
  • Can lower triglycerides by 20-40% 1
  • Important caveat: Recent 2025 AACE guidelines suggest EPA-only formulations over EPA+DHA combinations for hypertriglyceridemia with cardiovascular disease, as EPA+DHA showed no clinically meaningful cardiovascular benefit 6

For Severe Hypertriglyceridemia (≥500 mg/dL)

  • Target: 2-4 grams/day EPA+DHA 2
  • Requires physician supervision due to potential bleeding risk at high doses 1

Practical Dosing Algorithm

Step 1: Identify the actual EPA and DHA content per capsule from your product label (not just total omega-3)

Step 2: Calculate capsules needed based on your clinical situation:

  • No heart disease: Aim for 500 mg EPA+DHA daily
  • Known heart disease: Aim for 1,000 mg EPA+DHA daily
  • High triglycerides: Aim for 2,000-4,000 mg EPA+DHA daily under physician care

Step 3: Verify you're not exceeding safety thresholds:

  • Up to 5 g/day combined EPA+DHA is generally safe for long-term use 7
  • Doses >3 g/day should be taken under physician supervision 1

Important Safety Considerations

Bleeding risk: Very high intakes may cause excessive bleeding in some individuals, though long-term supplementation up to 5 g/day has not increased spontaneous bleeding episodes 1, 7

Atrial fibrillation: Pharmacological doses (≥4 g/day) show a small but consistent increased risk of atrial fibrillation 6

LDL cholesterol: EPA+DHA combinations at 4 g/day may increase LDL cholesterol by ~3% in patients with very high triglycerides, though EPA-only formulations do not 8

Formulation matters: Triglyceride-form supplements are more bioavailable than ethyl ester forms 9. Most effective protocols use ≥1,000 mg/day for at least 12 weeks 9

Recent Evidence Shift (2025)

The most recent AACE guidelines 6 represent a significant change: they now suggest against EPA+DHA combinations for hypertriglyceridemia in patients with or at risk for cardiovascular disease, based on trials showing no meaningful cardiovascular benefit at 1.8 g/day. However, they conditionally support EPA-only formulations (icosapent ethyl) for this indication.

Bottom line: If you have cardiovascular disease or risk factors with elevated triglycerides, discuss with your physician whether an EPA-only prescription formulation (like icosapent ethyl 4 g/day) would be more appropriate than your current EPA+DHA supplement 6.

References

Guideline

american association of clinical endocrinology clinical practice guideline on pharmacologic management of adults with dyslipidemia.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.